{
  "functional_evidence_assessment": [
    {
      "variant_id": {
        "Gene": "PARK2",
        "Protein_Change": {
          "ref": "Not_Extracted",
          "alt": "Not_Extracted",
          "position": "Not_Extracted"
        },
        "variant_string_id": "PARK2_Not_Extracted"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "The paper states that PARK2 mutations in cancer occur in the same domains and sometimes at the same residues as germline mutations causing familial Parkinson's disease. These mutations abrogate the growth-suppressive effects of PARK2 and decrease its E3 ligase activity, leading to mitotic instability.",
          "judgment": "Yes",
          "reasoning": "The paper explicitly defines the disease mechanism: PARK2 mutations disrupt E3 ligase activity and ubiquitination of cyclin E, a key function in tumor suppression."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The paper does not describe specific assays for individual variants but notes that PARK2 mutations in cancer 'abrogate growth-suppressive effects' and 'decrease E3 ligase activity'.",
          "judgment": "No",
          "reasoning": "The paper lacks explicit descriptions of functional assays (e.g., enzyme activity, protein interaction, or cell-based assays) used to test individual variants. General mechanistic claims are made without variant-specific experimental validation.",
          "next_step_or_outcome": "Do not use PS3/BS3"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "N/A"
      },
      "overall_conclusion": "No specific variants with functional evidence were described in the provided text. The paper discusses PARK2 mutations broadly without quantifying functional impacts on individual variants. Functional evidence strength cannot be assigned per ACMG guidelines."
    }
  ]
}